Introduction
The malignant lymphomas were the first solid tumours demonstrated to be curable by chemoradiotherapy. Despite the evolution in the last 20 years of more intensive and more successful chemotherapy schedules, about 30% of patients with Hodgkin's disease'"2 and at least 50% of those with intermediate and high-grade non-Hodgkin's lymphoma,3 will die of their disease.
It has been appreciated for some time that patients receiving suboptimal therapy for lymphoma fare less well than those receiving full treatment, and thus dose escalation to eradicate resistant or relapsed tumour has some theoretical merit. A significant increase in dose intensity cannot be achieved without potentially lethal prolonged bone marrow failure. This may be prevented by aspirating some of the patient's bone marrow and re-infusing this following chemoradiotherapy conditioning. Autologous bone marrow transplantation (ABMT) was first attempted in the 1950s, but results were poor due partly to inadequate dosage escalation to eradicate tumour and partly because techniques of bone marrow harvest and cryopreservation were ill-understood. 4 The development of allogeneic bone marrow transplantation in the 1970s, with the realization that cryopreserved marrow could successfully be used to salvage patients receiving massive conditioning therapy, led to a re-awakening ofinterest in ABMT in lymphoma. 20 There is, however, now broad agreement on the indications for ABMT amongst Centres reporting substantial series ofpatients.2' These are: (a) failure to achieve first complete remission with satisfactory induction therapy; (b) relapse within 6 months of attaining complete remission with conventional first line therapy; and (c) failure to maintain remission after treatment with two different modalities of therapy, that is, either relapse from second remission or failure to achieve a second remission after relapse from first remission.
In Although comparison with historical data suggests that ABMT may confer a survival advantage for patients with high-grade NHL who have achieved a second complete response or have responding disease, there are no published data from randomized prospective trials to confirm these findings. The Parma study29 which randomizes patients with responding relapse to either additional conventional treatment or ABMT is attempting to answer this difficult question.
Since it is apparent that patients with advanced disease do less favourably, ABMT is being explored earlier in the treatment of NHL. Encouraging results have been obtained in a number of non-randomized studies30 and two prospective randomized trials are underway in Europe for highrisk high-grade non-Hodgkin's lymphoma and lymphoblastic lymphoma.
Low-grade NHL
Low-grade lymphoma is usually a disease of the elderly. It has an insidious course characterized by repeated responsiveness to chemotherapy or radiotherapy, but relapse and eventual death from tumour is inevitable. The median survival is quite long at about 10 years.3"32 In older patients a conservative approach is justified but younger patients may warrant more experimental aggressive therapy. Early results of ABMT are encouraging23'33 with transplanted patients doing more favourably than historical age-and diseasematched controls (Rohatiner, 1993, personal communication). A European trial of ABMT versus further conventional treatment for younger poorrisk patients with follicular lymphoma has recently commenced.
Transplant-related mortality ABMT has frequently been offered to heavily pretreated patients with advanced disease. In these circumstances it is not surprising that a transplantrelated mortality of up to 31% has been reported. 7 The principal causes of death are sepsis and pneumonitis. Pneumonitis is particularly troublesome in patients who have already received mediastinal radiotherapy.8 Overall, the transplantrelated mortality is approximately 10%, although in some centres with good-risk patients, the mortality can be as low as 2%.23
Haemopoietic growth factors
The recent clinical availability of recombinant human haemopoietic growth factors (GM-CSF, G-CSF) together with more experimental cytokines (for example, IL3, IL6 and stem cell factor) has generated considerable interest in the stimulation of haemopoietic recovery following ABMT. Although it seems clear that the use of G-or GM-CSF results in about a 7-day reduction in the time to achieve a neutrophil count of 0.5 x 109/l after ABMT,34 evidence is mixed that this is translated in significant clinical benefit.3536 The most significant impact of the currently available growth factors may be to permit easier mobilization of peripheral progenitor cells which may be used to repopulate the marrow.
Peripheral progenitor cell transplants
It has been appreciated for some years that part of the mononuclear fraction ofperipheral white blood cells following recovery from intensive chemotherapy has the ability to repopulate the marrow.36
This technique was originally used primarily to reduce potential contamination of the graft with malignant cells. This is speculative, since it is not clear whether circulating progenitor cells are devoid of tumour cells with clonogenic potential. Using chemotherapy alone to mobilize cells is cumbersome and engraftment unpredictable. The situation has dramatically changed with the combination of G-or GM-CSF and chemotherapy (usually cyclophosphamide) to mobilize progenitor cells. Large numbers of progenitors can be harvested and their use results not only in a very considerable reduction in the duration of neutropenia, but also very rapid megakaryocyte engraftment. 37 39 Research is currently in hand to establish the most effective mobilizing schedules and many groups can harvest adequate cells with only one apheresis. The impact on clinical practice has been considerable. Most patients can now be discharged within 14 days of transplantation and it is likely that, despite the additional costs of growth factors and apheresis, progenitor cell transplants are considerably cheaper than ABMT.'
Conclusion
The last 10 years has seen an explosion ofinterest in the use of high-dose chemotherapy and marrow rescue in the management of malignant lymphomas. The development ofperipheral progenitor cell transplants, which promote rapid engraftment, with the promise of reduced morbidity and costs has further accelerated the trend to more intensive treatment. It should not be forgotten, however, that progenitor cell transplantation is only a tool to allow simpler exploration of the efficacy of dose escalation. It remains to be proved whether, in the context of chemotherapy, that more is necessarily better. These questions can only be answered in well-designed, prospective, randomized clinical trials. Experience to date suggests that such trials present ethical dilemmas both to physicians and patients, and accrual of adequate numbers may be difficult because of a widespread perception, possibly fallacious, that transplantation is better than the best available conventional salvage treatment.
